Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Fagin

Showing results (191-200 of 261) with videos related to

Pageof 27
Sort By:
Cancer Cell|September 14, 2016
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF SignalingZoi Karoulia, Yang Wu, Tamer A Ahmed, et al.
Cancer Research|June 3, 2009
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1Julio C Ricarte-Filho, Mabel Ryder, Dhananjay A Chitale, et al.
Endocrinology|March 31, 1999
Targeted overexpression of parathyroid hormone-related protein (PTHrP) to vascular smooth muscle in transgenic mice lowers blood pressure and alters vascular contractilityS Maeda, R L Sutliff, J Qian, et al.
The Journal of Clinical Endocrinology and Metabolism|November 7, 2003
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomasMarina N Nikiforova, Edna T Kimura, Manoj Gandhi, et al.
Cancer Research|July 20, 2007
The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cellsNagako Akeno-Stuart, Michelle Croyle, Jeffrey A Knauf, et al.
Human Molecular Genetics|September 24, 2013
Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formationAlice F Goodwin, William E Tidyman, Andrew H Jheon, et al.
Cancer Research|May 16, 2018
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid CancersBrian R Untch, Vanessa Dos Anjos, Maria E R Garcia-Rendueles, et al.
Molecular Cancer Therapeutics|November 18, 2021
Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor ActivityYiyu Dong, Yongxing Gong, Fengshen Kuo, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2009
Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogeneXu Chen, Norisato Mitsutake, Krista LaPerle, et al.
Gut|December 14, 2004
Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injuryS Sanz, J B Pucilowska, S Liu, et al.
Pageof 27

Showing results (191-200 of 261) with videos related to

Sort By:
Pageof 27
Cancer Cell|September 14, 2016
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF SignalingZoi Karoulia, Yang Wu, Tamer A Ahmed, et al.
Cancer Research|June 3, 2009
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1Julio C Ricarte-Filho, Mabel Ryder, Dhananjay A Chitale, et al.
Endocrinology|March 31, 1999
Targeted overexpression of parathyroid hormone-related protein (PTHrP) to vascular smooth muscle in transgenic mice lowers blood pressure and alters vascular contractilityS Maeda, R L Sutliff, J Qian, et al.
The Journal of Clinical Endocrinology and Metabolism|November 7, 2003
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomasMarina N Nikiforova, Edna T Kimura, Manoj Gandhi, et al.
Cancer Research|July 20, 2007
The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cellsNagako Akeno-Stuart, Michelle Croyle, Jeffrey A Knauf, et al.
Human Molecular Genetics|September 24, 2013
Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formationAlice F Goodwin, William E Tidyman, Andrew H Jheon, et al.
Cancer Research|May 16, 2018
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid CancersBrian R Untch, Vanessa Dos Anjos, Maria E R Garcia-Rendueles, et al.
Molecular Cancer Therapeutics|November 18, 2021
Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor ActivityYiyu Dong, Yongxing Gong, Fengshen Kuo, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2009
Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogeneXu Chen, Norisato Mitsutake, Krista LaPerle, et al.
Gut|December 14, 2004
Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injuryS Sanz, J B Pucilowska, S Liu, et al.
Pageof 27